Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan

doi:10.3389/fmed.2021.749863

Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma

Front Med (Lausanne). 2021 Dec 3:8:749863. doi: 10.3389/fmed.2021.749863. eCollection 2021.

Authors

Jiao Cai¹, Ling Qiu¹, Lei Ma¹, Nan Zhang¹, Fang-Yi Fan¹

Affiliation

¹ Department of Hematology and Hematopoietic Stem Cell Transplantation Centre, General Hospital of the Chinese People's Liberation Army Western Theater, Chengdu, China.

Abstract

The standardized treatment plan for patients with plasmablastic lymphoma (PBL) remains controversial. Taking morphological characteristics and immunophenotypes into consideration may provide superior options for the treatment of PBL. In this case, we report that a myeloma-type regimen containing bortezomib plus cyclophosphamide, epirubicin, vindesine and prednisolone (CDOP) followed by sequential autologous hematopoietic stem cell transplantation (ASCT) and lenalidomide-based maintenance therapy to treat PBL may represent a promising regimen to improve the prognosis.

Keywords: 18F-FDG PET/CT; autologous hematopoietic stem cell transplantation; bortezomib; lenalidomide; plasmablastic lymphoma.

Publication types

Case Reports